Asymchem Laboratories (06821) reported a net profit attributable to shareholders of approximately RMB 852 million for the first three quarters, up 6.49% year on year.
Asymchem Laboratories (06821) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB 5.395 billion, up 16.52% year on year; net profit attributable to shareholders of the listed company of approximately RMB 852 million, up 6.49% year on year; and basic earnings per share of RMB 2.36.
Asymchem Laboratories (06821) announced its results for the first three quarters of 2026, with operating revenue of approximately RMB 5.395 billion, up 16.52% year on year; net profit attributable to shareholders of the listed company of approximately RMB 852 million, up 6.49% year on year; and basic earnings per share of RMB 2.36.
Related Articles
AK MEDICAL (01789) repurchased 50,000 shares on October 22 for approximately HK$214,200.
XUNFEIHEALTH (02506) Fully Completes Major Upgrade of Spark Medical Large Model Trained on Fully Domestic Computing Power; Spark Medical Large Model V3.7 Officially Released
CNBM (03323) completes issuance of RMB 3 billion corporate bonds
AK MEDICAL (01789) repurchased 50,000 shares on October 22 for approximately HK$214,200.
XUNFEIHEALTH (02506) Fully Completes Major Upgrade of Spark Medical Large Model Trained on Fully Domestic Computing Power; Spark Medical Large Model V3.7 Officially Released
CNBM (03323) completes issuance of RMB 3 billion corporate bonds
